Access cutting-edge hepatocellular carcinoma treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.
Access hepatocellular carcinoma specialists in Birmingham at no cost
This study follows strict safety protocols and ethical guidelines
All study-related hepatocellular carcinoma treatment provided free
The primary objectives of Cohort A Phase 1b are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepatocellular Carcinoma (HCC) and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of TTI-101 as a single agent. The primary objectives of Cohort A Phase 2 are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent at the
Sponsor: Tvardi Therapeutics, Incorporated
Check if you qualify for this hepatocellular carcinoma clinical trial in Birmingham, AL
If you're searching for hepatocellular carcinoma treatment options in Birmingham, AL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced hepatocellular carcinoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.